Literature DB >> 33591950

TMEM106C contributes to the malignant characteristics and poor prognosis of hepatocellular carcinoma.

Jicheng Duan1, Youwen Qian2, Xiaohui Fu1, Meiling Chen3, Kai Liu1, Hu Liu1, Jiahe Yang1, Chen Liu1, Yanxin Chang1.   

Abstract

Transmembrane protein (TMEM) is a kind of integral membrane protein that spans biological membranes. The functions of most members of the TMEM family are unknown. Here, we conducted bioinformatic analysis and biological validation to investigate the role of TMEM106C in HCC. First, GEPIA and OncomineTM were used to analyze TMEM106C expression, which was verified by real-time PCR and western blot analyses. Then, the biological functions of TMEM106C were explored by CCK8 and transwell assays. The prognostic value of TMEM106C was analyzed by UALCAN. LinkedOmics was used to analyze TMEM106C pathways generated by Gene Ontology. A protein-protein interaction network (PPI) was constructed by GeneMANIA. We demonstrated that TMEM106C was overexpressed in HCC and that inhibition of TMEM106C significantly suppressed the proliferation and metastasis of HCC through targeting CENPM and DLC-1. Upregulation of TMEM106C was closely correlated with sex, tumor stage, tumor grade and prognosis. Overexpression of TMEM106C was linked to functional networks involving organelle fission and cell cycle signaling pathways through the regulation of CDK kinases, E2F1 transcription factors and miRNAs. Our data demonstrated that TMEM106C contributes to malignant characteristics and poor prognosis in HCC, which may serve as a prognostic biomarker and potential therapeutic target.

Entities:  

Keywords:  TMEM106C; bioinformatics; hepatocellular carcinoma; metastasis; proliferation

Mesh:

Substances:

Year:  2021        PMID: 33591950      PMCID: PMC7950261          DOI: 10.18632/aging.202487

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  63 in total

1.  Overexpression and biological function of TMEM48 in non-small cell lung carcinoma.

Authors:  Wenliang Qiao; Yudong Han; Wei Jin; Mi Tian; Pei Chen; Jie Min; Haiyang Hu; Binbin Xu; Wenzhuo Zhu; Liwen Xiong; Qiang Lin
Journal:  Tumour Biol       Date:  2015-09-21

2.  Targeting CDK1 and MEK/ERK Overcomes Apoptotic Resistance in BRAF-Mutant Human Colorectal Cancer.

Authors:  Peng Zhang; Hisato Kawakami; Weizhen Liu; Xiangyu Zeng; Klaus Strebhardt; Kaixiong Tao; Shengbing Huang; Frank A Sinicrope
Journal:  Mol Cancer Res       Date:  2017-12-12       Impact factor: 5.852

3.  The tumor suppressor DLC1 inhibits cancer progression and oncogenic autophagy in hepatocellular carcinoma.

Authors:  Hui-Ta Wu; Cheng-Rong Xie; Jie Lv; He-Qiang Qi; Fei Wang; Sheng Zhang; Qin-Liang Fang; Fu-Qiang Wang; Yu-Yan Lu; Zhen-Yu Yin
Journal:  Lab Invest       Date:  2018-05-21       Impact factor: 5.662

Review 4.  Hepatocellular carcinoma: epidemiology and molecular carcinogenesis.

Authors:  Hashem B El-Serag; K Lenhard Rudolph
Journal:  Gastroenterology       Date:  2007-06       Impact factor: 22.682

5.  The role of microRNA expression pattern in human intrahepatic cholangiocarcinoma.

Authors:  Lei Chen; He-Xin Yan; Wen Yang; Liang Hu; Le-Xin Yu; Qiong Liu; Liang Li; Dan-Dan Huang; Jin Ding; Feng Shen; Wei-Ping Zhou; Meng-Chao Wu; Hong-Yang Wang
Journal:  J Hepatol       Date:  2008-11-21       Impact factor: 25.083

6.  Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma.

Authors:  Elisa Wurmbach; Ying-bei Chen; Greg Khitrov; Weijia Zhang; Sasan Roayaie; Myron Schwartz; Isabel Fiel; Swan Thung; Vincenzo Mazzaferro; Jordi Bruix; Erwin Bottinger; Scott Friedman; Samuel Waxman; Josep M Llovet
Journal:  Hepatology       Date:  2007-04       Impact factor: 17.425

Review 7.  Deleted in liver cancer-1 (DLC1): an emerging metastasis suppressor gene.

Authors:  Nicholas C Popescu; Steve Goodison
Journal:  Mol Diagn Ther       Date:  2014-06       Impact factor: 4.074

Review 8.  Biological heterogeneity and versatility of cancer-associated fibroblasts in the tumor microenvironment.

Authors:  Luke Bu; Hideo Baba; Naoya Yoshida; Keisuke Miyake; Tadahito Yasuda; Tomoyuki Uchihara; Patrick Tan; Takatsugu Ishimoto
Journal:  Oncogene       Date:  2019-02-28       Impact factor: 9.867

9.  Knockdown of TMEM14A expression by RNAi inhibits the proliferation and invasion of human ovarian cancer cells.

Authors:  Qingmei Zhang; Xiufeng Chen; Xuan Zhang; Jingfen Zhan; Jie Chen
Journal:  Biosci Rep       Date:  2016-02-19       Impact factor: 3.840

10.  LinkedOmics: analyzing multi-omics data within and across 32 cancer types.

Authors:  Suhas V Vasaikar; Peter Straub; Jing Wang; Bing Zhang
Journal:  Nucleic Acids Res       Date:  2018-01-04       Impact factor: 16.971

View more
  4 in total

1.  TMEM92 acts as an immune-resistance and prognostic marker in pancreatic cancer from the perspective of predictive, preventive, and personalized medicine.

Authors:  Simeng Zhang; Xing Wan; Mengzhu Lv; Ce Li; Qiaoyun Chu; Guan Wang
Journal:  EPMA J       Date:  2022-07-04       Impact factor: 8.836

2.  LINC00238 inhibits hepatic carcinoma progression by activating TMEM106C‑mediated apoptosis pathway.

Authors:  Caihua Jiang; Feng Li; Meng Yang; Jianping Duan; Jianming Lai; Shulun Sun; Shaohua Fan
Journal:  Mol Med Rep       Date:  2021-09-03       Impact factor: 3.423

3.  Transmembrane Protein-Based Risk Model and H3K4me3 Modification Characteristics in Lung Adenocarcinoma.

Authors:  Tao Fan; Yu Liu; Hengchang Liu; Liyu Wang; He Tian; Yujia Zheng; Bo Zheng; Liyan Xue; Chunxiang Li; Jie He
Journal:  Front Oncol       Date:  2022-03-22       Impact factor: 6.244

4.  A transmembrane protein family gene signature for overall survival prediction in osteosarcoma.

Authors:  Yuehui Du; Xiaohui Zeng; Weiwei Yu; Wei Xie
Journal:  Front Genet       Date:  2022-08-05       Impact factor: 4.772

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.